Forty Seven Inc. (FTSV)’s Financial Results Comparing With Immune Design Corp. (NASDAQ:IMDZ)

Both Forty Seven Inc. (NASDAQ:FTSV) and Immune Design Corp. (NASDAQ:IMDZ) are Biotechnology companies, competing one another. We will compare their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Forty Seven Inc. N/A 0.00 65.49M -2.06 0.00
Immune Design Corp. 2.21M 128.31 53.14M -1.14 0.00

In table 1 we can see Forty Seven Inc. and Immune Design Corp.’s gross revenue, earnings per share and valuation.


Table 2 shows us Forty Seven Inc. and Immune Design Corp.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Forty Seven Inc. 0.00% 0% 0%
Immune Design Corp. -2,404.52% -43.4% -40.3%


The current Quick Ratio of Forty Seven Inc. is 11.9 while its Current Ratio is 11.9. Meanwhile, Immune Design Corp. has a Current Ratio of 13.1 while its Quick Ratio is 12.9. Immune Design Corp. is better positioned to pay off its short-term and long-term debts than Forty Seven Inc.


Immune Design Corp. also pays out annual dividends at $0.22 per share and at a 3.84% dividend yield. No dividend is paid out for Forty Seven Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Forty Seven Inc. and Immune Design Corp.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Forty Seven Inc. 0 0 0 0.00
Immune Design Corp. 0 2 0 2.00

Competitively the consensus target price of Immune Design Corp. is $5.93, which is potential 1.37% upside.

Insider and Institutional Ownership

Roughly 67.3% of Forty Seven Inc. shares are held by institutional investors while 81.7% of Immune Design Corp. are owned by institutional investors. About 5.1% of Forty Seven Inc.’s share are held by insiders. Competitively, insiders own roughly 0.9% of Immune Design Corp.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Forty Seven Inc. 1.35% 17.43% -6.15% 12.09% 0% 9.73%
Immune Design Corp. 0.17% 273.72% 338.35% 68.99% 97.63% 348.46%

For the past year Forty Seven Inc. was less bullish than Immune Design Corp.


Immune Design Corp. beats on 8 of the 11 factors Forty Seven Inc.

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. It primarily develops oncology product candidates based on its ZVex and GLAAS product discovery platforms. The company's products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma. In addition, its technologies are also used in the fields of infectious diseases and allergies. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.